Malhotra Jaideep, Malhotra Keshav, Kamat Sudesh, Mishra Akansha, Chatterjee Charulata, Nair Seema, Ghosh Pranay, Mehta Rajvi, Bhadraka Harsha, Srinivas Sapna, Kumar Lalith, Mistry Rushika, Goenka Deepak, Kant Gaurav
Managing Director, Rainbow IVF, Agra, Uttar Pradesh, President ISAR (2019), India.
MBBS, MCE, Chief Embryologist & Director-Rainbow IVF, Agra (Uttar Pradesh), India.
J Hum Reprod Sci. 2021 Nov;14(Suppl 1):S3-S30. doi: 10.4103/0974-1208.330501. Epub 2021 Nov 16.
What are the good practices for the use of ADD-ON Treatments in IVF cycles in INDIA?
Add on treatments in IVF are procedures and technologies which are offered to patients in hope of improving the success rates. A lot of add on treatments exist; most of them have limited evidence and data for the Indian patient population is miniscule. These interventions may have limited effects, so it is imperative that any new technology that is offered is evaluated properly and has enough evidence to suggest that it is safe and effective.
This is the report of a 2-day consensus meeting where two moderators were assigned to a group of experts to collate information on Add on treatments in IVF in INDIA. This meeting utilised surveys, available scientific evidence and personal laboratory experience into various presentations by experts on pre-decided specific topics.
PARTICIPANTS/MATERIALS SETTING METHODS: Expert professionals from ISAR representing clinical and embryology fields.
The report is divided in various components including the health of the Offspring, the various ADD ons available to an ART center, consensus points for each technology & qualifications and trainings for embryologists, the report and recommendations of the expert panel reflect the discussion on each of the topics and try to lay down good practice points for labs to follow.
The recommendations are solely based on expert opinion. Future availability of data may warrant an update of the same.
These guidelines can help labs across the country to standardise their ART services and improve clinical outcomes, it will also motivate clinics to collect data and report the use of Add ons to the national registry.
STUDY FUNDING/COMPETING INTERESTS: The consensus meeting and writing of the paper was supported by funds from CooperSurgical India.
印度试管婴儿周期中附加治疗的良好实践有哪些？
试管婴儿中的附加治疗是向患者提供的旨在提高成功率的程序和技术。存在许多附加治疗；其中大多数证据有限，针对印度患者群体的数据极少。这些干预措施可能效果有限，因此必须对提供的任何新技术进行适当评估，并要有足够证据表明其安全有效。
这是一份关于为期两天的共识会议的报告，会上两名主持人被分配到一组专家中，以整理印度试管婴儿附加治疗的信息。本次会议将调查、现有科学证据和个人实验室经验纳入专家就预先确定的特定主题进行的各种陈述中。
参与者/材料设置方法：来自印度辅助生殖协会（ISAR）的代表临床和胚胎学领域的专家专业人员。
该报告分为多个部分，包括后代健康、ART中心可用的各种附加治疗、每种技术的共识要点以及胚胎学家的资质和培训，专家小组的报告和建议反映了对每个主题的讨论，并试图为实验室制定良好的实践要点以供遵循。
这些建议完全基于专家意见。未来数据的可得性可能需要对其进行更新。
这些指南可帮助全国的实验室规范其ART服务并改善临床结果，还将促使诊所收集数据并向国家登记处报告附加治疗的使用情况。
研究资金/利益冲突：本次共识会议及论文撰写得到了印度库珀外科公司的资金支持。
